Exclusion criteria (67)Patient cohort <100 (50)Re-analysis of same cohort (5)Off topic (12)

Studies on genetic polymorphisms in Hodgkin

N=112

Unique studies selected for review

N=45

*7 studies shared between non-HLA susceptibility and prognosis**1 study shared between prognosis and secondary malignancies/toxicities

HLAsusceptibility

N=11

Non-HLA susceptibility

N=19

GWASN=5

PrognosisN=15*

Secondary malignancies/ toxicities

N=3**

Supplementary figure 1.